FTC approves Sun Pharma’s $4bn Ranbaxy merger

The US Federal Trade Commission (FTC) has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Intubated patients sedative patent the focus of ACS Dobfar suit

16 December 2021 Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Generics

NJ judge invalidates Sun patent in BromSite suit

5 October 2021 A New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals.

More on this story

Americas

Intubated patients sedative patent the focus of ACS Dobfar suit

16 December 2021 Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Generics

NJ judge invalidates Sun patent in BromSite suit

More on this story

Americas

Intubated patients sedative patent the focus of ACS Dobfar suit

16 December 2021 Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Generics

NJ judge invalidates Sun patent in BromSite suit